Alopecia Areata study: Deuruxolitinib
Official title Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
ClinicalTrials.gov ID: NCT07133308
What this study is testing
What is Deuruxolitinib?
An investigational oral tablet being studied as a potential treatment for alopecia areata in adolescents. It is designed to inhibit JAK1 and JAK2 enzymes, which may reduce inflammatory signaling involved in hair loss.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out if the drug deuruxolitinib is safe and effective for treating severe hair loss.
- Who it's for
- The study is looking for adolescents between 12 and 17 years old who have lost 50% or more of their scalp hair.
- What's involved
- Participants will take the study medicine and visit the clinic for check-ups and tests to monitor their health and hair growth.
- Time commitment
- The source text does not specify the total duration or the number of required visits.
- Phase 3: a large, late-stage study
- Time commitment: about 24 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 17
You may be able to join if
- Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years.
- Between 12 to \<18 years of age
- At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50.
- Willing to comply with the study visits and requirements of the study protocol
You likely can't join if
- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other...
- Treatment with other medications or agents within 28 days of Baseline or during the study that may affect hair regrowth or immune response.
- Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
- Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the...
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Scottsdale, Arizona, United States
- Bryant, Arkansas, United States
- Bakersfield, California, United States
- Fremont, California, United States
- Los Angeles, California, United States
- Palm Springs, California, United States
- San Diego, California, United States
- Denver, Colorado, United States
- Wheat Ridge, Colorado, United States
- Doral, Florida, United States
- Hollywood, Florida, United States
- Kissimmee, Florida, United States
- Miami, Florida, United States
- Miami Lakes, Florida, United States
- Pompano Beach, Florida, United States
- Sanford, Florida, United States
- Sweetwater, Florida, United States
- Cumming, Georgia, United States
- Macon, Georgia, United States
+ 36 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 24 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Scottsdale, Arizona, United States; Bryant, Arkansas, United States; Bakersfield, California, United States; Fremont, California, United States; Los Angeles, California, United States and 50 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.